Skip to main content

Table 6 Diagnostic power of IGF2 to discriminate patients with HCC from patients with cirrhosis in different three staging systems

From: A novel model based on interleukin 6 and insulin-like growth factor II for detection of hepatocellular carcinoma associated with hepatitis C virus

Classification AUC Sens% Spe% PPV% NPV% AC%
Number of nodules (n, %)
 Single (67, 43.2%) 0.90 88 73.3 67 92 80
 Multiple (88, 56.8) 0.86 79 73.3 73 82 78
Macrovascular invasion (n, %)
 Absent (141, 91%) 0.88 83 73.3 81 79 80
 Present (14, 9%) 0.88 80 73.3 36 96 77
Size of nodules (n, %)
 <2 (48, 31%) 0.85 75 73.3 56 89 76
 >2 (107, 69%) 0.89 86 73.3 77 85 81
BCLC stage (n, %)
 0-A (109, 70.3%) 0.88 77 73.3 77 79 77
 B (46, 29.7) 0.88 79 73.3 77 88 77
CLIP stage (n, %)
 0-1 (122, 79%) 0.88 84 73.3 77 82 80
 2-3 (33, 21%) 0.89 78 73.3 77 92 77
Okuda stage (n, %)
 Stage I (117, 75.5%) 0.89 87 73.3 79 85 82
 Stage II (38, 24.5%) 0.89 79 73.3 61 89 77